Events & News:
ADI is presenting at the following events:
Oct 5-11, 2023, Dakar, Senegal
Mar 10 -12, 2024, Philadelphia, USA
– Human milk antibodies to global pathogens reveal geographic and interindividual variations in IgA and IgG. Campo JJ, Seppo AE, Randall AZ, Pablo J, Hung C, Teng A, Shandling AD, Truong J, Oberai A, Miller J, Iqbal NT, Peñataro Yori P, Kukkonen AK, Kuitunen M, Guterman LB, Morris SK, Pell LG, Al Mahmud A, Ramakrishan G, Heinz E, Kirkpatrick BD, Faruque AS, Haque R, Looney RJ, Kosek MN, Savilahti E, Omer SB, Roth DE, Petri WA Jr, Järvinen KM. J Clin Invest. (2024) 134(15):e168789. PMID: 39087469; PMCID: PMC11290967. Read more.
– Genomic and panproteomic analysis of the development of infant immune responses to antigenically-diverse pneumococci. Nicholas Croucher, Joseph Campo, Timothy Le, Jozelyn Pablo, Christopher Hung, Andy Teng, Claudia Turner, François Nosten, Stephen Bentley, Xiaowu Liang, Paul Turner, and David Goldblatt. Nat Commun 15, 355 (2024). https://doi.org/10.1038/s41467-023-44584-2 Read more.
– Identification of broadly-conserved parasitic nematode proteins that activate immunity. Bruce A. Rosa, Dante S. Zarlenga, Valsin M. Fournet, Ethiopia Beshah, Dolores E. Hill, Alexander Zarlenga, Angela Yee, Xiaowu Liang, Adam D. Shandling, Amit Oberai, Joseph F. Urban Jr. and Makedonka Mitreva. J Front. Parasitol., 08 August 2023, Sec. Parasitology Omics Volume 2 – 2023 Read more.
– Specific Cryptosporidium antigens associate with reinfection immunity and protection from cryptosporidiosis. Gilchrist CA, Campo JJ, Pablo JV, Ma JZ, Teng A, Oberai A, Shandling AD, Alam M, Kabir M, Faruque AS, Haque R, Petri WA Jr. J Clin Invest. 2023 Jun 22:e166814. doi: 10.1172/JCI166814. Epub ahead of print. PMID: 37347553. Read more.
May, 2023 – Use of an ETEC Proteome Microarray to Evaluate Cross-Reactivity of ETVAX® Vaccine-Induced IgG Antibodies in Zambian Children. Mubanga C, Simuyandi M, Mwape K, Chibesa K, Chisenga C, Chilyabanyama ON, Randall A, Liang X, Glashoff RH, Chilengi R. Vaccines (Basel). 2023 May 4;11(5):939. doi: 10.3390/vaccines11050939. PMID: 37243042; PMCID: PMC10224314. Read more.
May, 2023 – Characterization of SARS-CoV-2 antibodies in human milk from 21 women with confirmed COVID-19 infection. Bode L, Bertrand K, Najera JA, Furst A, Honerkamp-Smith G, Shandling AD, Chambers CD, Camerini D, Campo JJ. Pediatr Res. 2023 May;93(6):1626-1633. doi: 10.1038/s41390-022-02360-w. Epub 2022 Nov 25. PMID: 36434204; PMCID: PMC9702863. Read more.
May, 2022 – Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection. Macià D, Campo JJ, Moncunill G, Jairoce C, Nhabomba AJ, Mpina M, Sorgho H, Dosoo D, Traore O, Kusi KA, Williams NA, Oberai A, Randall A, Sanz H, Valim C, Asante KP, Owusu-Agyei S, Tinto H, Agnandji ST, Kariuki S, Gyan B, Daubenberger C, Mordmüller B, Petrone P, Dobaño C. JCI Insight. 2022 May 23;7(10):e158030. doi: 10.1172/jci.insight.158030. PMID: 35446785; PMCID: PMC9220828. Read more.
2022 – Panproteome Analysis of the Human Antibody Response to Bacterial Vaccines and Challenge. Campo JJ, Oberai A. Methods Mol Biol. 2022;2414:75-96. doi: 10.1007/978-1-0716-1900-1_6. PMID: 34784033. Read more.
2021 – Multipathogen Analysis of IgA and IgG Antigen Specificity for Selected Pathogens in Milk Produced by Women From Diverse Geographical Regions: The INSPIRE Study. McGuire MK, Randall AZ, Seppo AE, Järvinen KM, Meehan CL, Gindola D, Williams JE, Sellen DW, Kamau-Mbuthia EW, Kamundia EW, Mbugua S, Moore SE, Prentice AM, Foster JA, Otoo GE, Rodríguez JM, Pareja RG, Bode L, McGuire MA, Campo JJ. Front Immunol. 2021 Feb 11;11:614372. doi: 10.3389/fimmu.2020.614372. PMID: 33643297; PMCID: PMC7905217. Read more.
Publications:
ADI’s innovative and versatile platform has been successfully used to screen and discover important antigens or biomarkers in various studies ranging from pathogenesis to the development of diagnostics and vaccines. This has been documented in over 130 scientific publications by ADI scientists and worldwide collaborators.
| Name |
|---|
| Babesia |
| Bartonella |
| Borrelia |
| Brucella |
| Burkholderia |
| Candidemia |
| Chlamydia |
| Coxiella |
| Escherichia coli |
| Francisella |
| Leptospira |
| Mycobacterium |
| Salmonella |
| Shigella |
| Staphylococcus |
| Streptococcus |
| Name |
|---|
| HIV |
| HPV |
| HSV |
| Orthopoxvirus |
| SARS-CoV-2 |
| Zika virus |
| Name |
|---|
| Cryptosporidium |
| Cytauxzoon |
| Plasmodium |
| Onchocerca |
| Schistosomiasis |
| Toxoplasmosis |
| Autoimmune |
| T-Cell Screening |
| General |
White Papers:
Qualification of Antibody-Cross-Reactivity Using HuProt™ Protein Microarray Version 3.0
We have utilized a comprehensive human purified protein microarray- HuProt™ 3.0 platform to determine the specificity and binding of protein epitopes by commercial monoclonal antibody reagents. Qualification of cross-reactivity and off-target binding effects using protein microarray technology is an efficient and cost-effective method that enables rapid identification of high quality mAbs as reproducible protein specific reagents for research and clinical studies. Our results of probing five different monoclonal antibodies against three separate targets showed the inconsistent quality of antibodies in both, spot intensity and specificity. Our results add to the literature illustrating that the HuProt™ microarray is a well-suited platform to qualify monoclonal antibodies. Download here.
Frequently Asked Questions (FAQs):
How Does ADI Technology Work?
ADI’s proprietary platform uses cutting edge protein microarray technology, which allows for thousands or even tens of thousands of parallel assays to detect specific antibodies present in the biological specimen such as serum, plasma or saliva. Our approach allows researchers to profile the humoral immune response to an entire proteome.
What Are The Advantages Using ADI Microarray Technology?
We have created a versatile platform that allows for the parallel assaying of hundreds or thousands of proteins in one single assay. Our ever-growing inventory encompasses more than 60,000 proteins from over 30 microorganisms. Our analytic pipeline has been developed over the last 10 years to accurately, efficiently and reliably generate results. The power of our technology is demonstrated in over 00 scientific papers published by ADI and our collaborators. Now we offer our powerful proteomic technology with full service available to researchers and clinicians worldwide.
How Does ADI’s Technology Alleviate The Bottleneck Of Traditional Biomarker Discovery?
ADI’s proprietary platform uses cutting edge protein microarray technology, which allows for thousands or even tens of thousands of parallel assays to detect specific antibodies present in the biological specimen such as serum, plasma or saliva. Our approach allows researchers to profile the humoral immune response to an entire proteome.
- ADI’s Novel platform accelerates discovery (weeks vs. years) in high-throughput way
- We screen full or partial proteomes consisting of hundreds or thousands of proteins at once
- Only microliters of serum are needed per assay for hybridization
- ADI provides full service from highly reproducible microarray manufacturing to robust statistical analysis of serological results
What Types Of Studies Can Protein Microarrays Be Used For?
Both basic and clinical research studies that normally use an assay with a protein attached to a substrate for detection of various binding properties of proteins. For example: serological ELISA-like assays to profile antibody specificity, protein-protein interaction assays, identification of biomarkers in disease stages and kinase assays. Unlike traditional experiments, protein microarrays give you the ability to run hundreds or even thousands of parallel assays with minute amount of samples required.
How Is A Study Designed?
A typical study involves a comparison between a control group and one or more experimental groups. For example, a group of healthy donors can be compared to a group of donors with a particular disease or disease state or treatment such as vaccination. The experimental design will balance sample information related to the hypotheses being tested (e.g. control versus vaccinated) against technical factors such as day of probing to prevent technical variation from impacting conclusions.
How Many Serum Samples Are Required For Analysis?
The number of samples in each group depends on the biological variability of the immune response to your disease of interest. For example, a very homogeneous response to a virus may require tens of samples, whereas heterogeneous immune responses to bacteria or human disease may require hundreds to thousands. If relevant data is available from a pilot study or other source ADI can perform power calculations to help you determine how many samples to assay.
What Type Of Specimens Can Be Analyzed?
Serum, plasma, whole blood, ALS (antibodies in lymphocyte supernatant), fecal, breast milk, saliva, and other specimens that contain antibodies. If your specimen type is not listed here please contact us for more information.
How Should I Send You My Specimens?
The preferable method is frozen in dry ice, we have also used samples shipped on wet ice or dried on filter paper. Please make sure to send your samples at the beginning of the week to avoid delay over the weekend. It is helpful if you provide us with a tracking number.
How Much Material Is Required For Each Serum Sample?
Please send a 25-50 uL aliquot of your serum samples. If you have only limited quantities or need information for other specimen types please contact us for more information.
How Many Antibodies/Biomarkers Can Be Identified?
We can identify all immunologically reactive proteins displayed on a given full or partial proteome chip.
What Classes Or Isotype Of Antibodies Do You Detect?
We have experience detecting IgG, IgM, IgA, IgE and subclasses of IgG. We can also develop a new protocol if needed, so just ask.
What Is The Process For An Antibody Screening Service?
Fill out the contact form on the website. ADI will review your proposal and contact you to discuss the next steps including specimen shipping instructions. Raw data and an initial report will be provided within 90 days after receiving your samples.
What Kind Of Data Can I Expect From A Protein Microarray Study?
A HTML based report containing raw and normalized data, groups comparison with visual and quantitative presentations of the results based on execution of the predefined Statistical Analysis Plan (SAP).
How Much Does A Study Cost?
Once a study design is completed, the material cost of the study is calculated based on the type and number of arrays, and reagents required. For a study involving full service, the cost depends on the number of specimens, number of analytes and type of data report requested. Exact pricing can be determined from the submitted study proposal form.
How Are ADI ELISA Kits Different Than Other Manufacturers?
ADI ELISA kits are all developed using our full proteome microarray screening technology. We thoroughly examine the full proteome in order to select the best antigens for translation to an ELISA.
Does ADI Offer Microarray Training?
We do offer a one-week training course at our lab in Irvine, California. You will get hands-on experience in probing arrays as well as an introduction into the analysis. Please contact us for more information about our microarray training.
Can I Order Arrays And Do The Sample Probing In My Own Lab?
We are a contract research organization and offer full project service, which typically means that you will send us your specimens and we will carry out the experiment. You will receive a comprehensive HTML based report package containing the raw and normalized data along with agreed upon statistical analyses.